

1 SARS-CoV-2 screening in patients in need of urgent inpatient treatment in the Emergency  
2 Department (ED) by digitally integrated point-of-care PCR: A clinical cohort study

3 Martin Möckel<sup>1</sup>, Myrto Bolanaki<sup>1</sup>, Jörg Hofmann<sup>2</sup>, Angela Stein<sup>2</sup>, Jennifer Hitzek<sup>1</sup>, Fabian  
4 Holert<sup>1</sup>, Antje Fischer-Rosinsky<sup>1</sup> and Anna Slagman<sup>1</sup>

5

6 <sup>1</sup>Department of Emergency and Acute Medicine, Charité – Universitätsmedizin Berlin,  
7 Campus Mitte and Virchow and

8 <sup>2</sup>Institute of Virology, Charité - Universitätsmedizin Berlin and Labor Berlin - Charité Vivantes  
9 GmbH

10

11

12

13

14 Running title: SARS-CoV-2 screening in the ED

15

16 Word count: 2413

17

18

19

20

21

22

23

24

25

26

27 Correspondence to:

28 Univ.-Prof. Dr. med. Martin Möckel, FESC, FAHA

29 Department of Emergency and Acute Medicine

30 Campus Mitte and Virchow

31 Charité – Universitätsmedizin Berlin

32 Charitéplatz 1

33 10117 Berlin

34 Email: [martin.moeckel@charite.de](mailto:martin.moeckel@charite.de)

35

## 36 **Abstract**

37 Patients in need of urgent inpatient treatment were recruited prospectively. A rapid point of  
38 care PCR test (POC-PCR; Liat®) for SARS-CoV2 was conducted in the ED and a second PCR-  
39 test from the same swab was ordered in the central laboratory (CL-PCR). POC-PCR analyzers  
40 were digitally integrated in the laboratory information system.

41 Overall, 160 ED patients were included. A valid POC-PCR-test result was available in 96.3%  
42 (n=154) of patients. N=16 patients tested positive for SARS-CoV-2 (10.0%). The POC PCR test  
43 results were available within 102 minutes (median, IQR: 56-211), which was significantly  
44 earlier compared to the CL PCR (811 minutes; IQR: 533-1289,  $p < 0.001$ ). The diagnostic  
45 accuracy of the POC- PCR test was 100%. The implementation and digital LIS integration was  
46 successfully done. Staff satisfaction with the POC process was high.

47 The POC-PCR testing in the emergency department is feasible and shows a very high  
48 diagnostic performance.

49 Trial registration: DRKS00019207

## 50 Introduction

51 The COVID-19 pandemic put major challenges on Emergency Departments (ED)  
52 worldwide(1). One major aspect was that all urgent patients had to be treated mostly  
53 without knowing the SARS-CoV-2 status as laboratory based polymerase chain reaction  
54 (PCR)-test usually took at least 6-8 hours of turn-around-time (TAT)(2). The introduction of  
55 rapid antigen testing had the advantage of faster results on the cost of false negative results.  
56 Although some authors thought that false negative rapid antigen tests may due to low virus  
57 concentrations only(3), we could show that this is not true in clinical practice and that  
58 among false negatives are infectious patients with high virus load(4). Thus, specifically for

59 emergencies, which require immediate intervention or operation and probably airway-  
60 management like patients with multiple trauma, acute myocardial infarction or stroke, a  
61 rapid, point-of-care (POC) SARS-CoV-2 PCR test would be of utmost importance(5).  
62 POC testing is standard in the ED for clinical chemistry parameters like lactate, electrolytes  
63 or cardiac troponin. For molecular diagnostics there have been first attempts with influenza  
64 POC testing(6). Due to the high importance of the test results, which touch regulatory  
65 aspects like hygiene rules and due the fast disposition and transfers (i.e. operating theatre,  
66 ICU) of the high urgent patients, a digital integration of the POC device in the LIS seems  
67 mandatory. In addition, strict testing rules to guarantee correct results, staff safety and  
68 reliable results information for all involved health care professionals have to be applied.  
69 Finally, the used instrument and assay need to provide reliable results under routine  
70 conditions(7).  
71 Therefore, in the current study, a SARS-CoV-2 PCR POC analyzer was digitally integrated in  
72 the LIS and tests were run by ED staff in high urgent patients.

### 73 Methods

#### 74 *Patient population*

75 All inpatients are screened for SARS-CoV-2 in our ED. Patients were prospectively recruited  
76 once it became clear that an acute intervention of any kind was indicated.

#### 77 *Data collection and endpoints*

78 Clinical characteristics and in-hospital follow-up information of all included patients were  
79 extracted from electronic medical records.

80 The primary endpoint of the analyses was turn-around-time (TAT) of the POC-PCR as  
81 compared to TAT of the CL-PCR in relation to the first intervention. Secondary endpoints  
82 were diagnostic performance, staff satisfaction with test handling and transfer of test  
83 results, patient safety and description of further clinical endpoints (e.g. stay on the intensive  
84 care unit (ICU), extra-corporal membrane oxygenation (ECMO), in-hospital mortality).

#### 85 *Statistical Analysis*

86 Descriptive analyses included the calculation of relative and absolute frequencies as well as  
87 median and interquartile range (IQR). Statistical differences were calculated using the Chi-  
88 square test for categorical variables and the Mann-Whitney test for continuous variables. A  
89 p-value of less than 0.05 was considered statistically significant. Due to the exploratory  
90 nature of the analysis, no corrections were made for multiple testing.

#### 91 *Digital integration of POC analyzers*

92 Liat®POC analyzers (Roche Molecular Systems) were connected to the laboratory  
93 information system via the hospital LAN system and Roche infinity POC middleware. The  
94 POC test was ordered via the laboratory channel, a barcode was generated and put on the  
95 test tube. A triple test cartridge (SARS-CoV-2, influenza A & B) was used. The barcode was  
96 scanned by the POC instrument and identified the order. Once the analyzer completed the  
97 test run, results were automatically transferred. In the central (molecular biology) laboratory  
98 the POC test results were automatically confirmed and transferred to the hospital  
99 information system. The LIS-HIS interface was refreshed every 15min. Thus with a 20min  
100 testing time on the Liat® analyzers, the SARS-CoV-2 POC test results were digitally available  
101 hospital wide within a maximum of 35min after the start of test.

#### 102 *Hygiene concept and test execution*

103 As the work with potential contagious samples require specific hygiene rules, these were set  
104 up according to national regulations. One challenge was that these rules allow the SARS-  
105 CoV-2 sample handling outside a laboratory setting only, if it is performed by the protected  
106 person who did the swab. Therefore, we set up the procedure in the way that the POC test  
107 cartridge was filled in the isolation room of the patient. Once the cartridge was closed, it  
108 could be handled by another member of the staff, who started the test run of the  
109 instrument at a central location of the ED. The details of the test procedure are available in  
110 the supplemental material (S1). For standardization purposes known virus preparations and  
111 dilutions were measured. The transport media was directly pipetted into the test cartridge  
112 without further dilution in a buffer.

113 The digitally integrated use of the POC instrument in the ED is summarized in the figure 1.

#### 114 *Ethics*

115 The Ethics committee of the Charité approved the study as an amendment to a previous POC  
116 influenza investigation (EA2/204/19). The study was registered in the German Clinical Trials Registry  
117 (DRKS00019207).

#### 118 Results

##### 119 *Patient characteristics*

120 The population of patients in urgent need of inpatient treatment (n=160) consisted of 10.0%  
121 of patients tested positive for SARS-CoV-2 in POC-PCR-testing (n=16) and 86.3% who were  
122 tested negative (86.3%). In 6 patients an invalid result occurred. Figure 2 shows the patient  
123 flow diagram.

124 Of all patient, 43.1% (n=69) were women and the median age was 68 years (IQR: 51-78).

125 In confirmed SARS-CoV-2 cases by POC-PCR-testing, the proportion of female patients was  
126 50.0% (n=8) as compared to 41.3% (n=57) in patients who were tested negative for SARS-  
127 CoV-2 (table 1a). The most common symptoms in SARS-CoV-2 positive cases were Dyspnea  
128 (37.5%; n=6), fever and cough (25.0%; n=7 each) table 1b. Laboratory parameters are  
129 depicted in table 1b. Diagnostic accuracy of POC-PCR was compared to CL-PCR (reference  
130 method) in all patients in urgent need of inpatient treatment. The resulting diagnostic  
131 performance values are: sensitivity 100% (95%-CI: 79-100), specificity 100% (95%-CI: 97-  
132 100), PPV and NPV 100% (table 2). The most common reasons for urgent need of inpatient  
133 treatment were admission to ICU (25.0%; n=40), urgent operation (22.5%, n=36) and stroke  
134 (18.1%; n=29; table 3).

#### 135 *Primary endpoint*

136 The POC PCR test was available within 102 minutes (median, IQR: 56-211) after admission,  
137 which was significantly earlier compared to the CL PCR (811 min; IQR: 533-1289,  $p < 0.001$ ).  
138 In 77.4% of patients the first relevant intervention depending on the inclusion criteria (acute  
139 severe trauma, stroke, myocardial infarction, operation, intervention needed within 6 hours  
140 after presentation, ICU admission needed within 6 hours after presentation) was done  
141 within 6 hours (n=113). The POC test result was available before the intervention in 92.1%  
142 (n=129) compared to 5.4% test results from the CL (n=8). There were no positive influenza  
143 tests.

#### 144 *Standard sample measurements*

145 We measured standard samples provided by the institute of virology with the following  
146 results.

147 Ct-values of the calibration samples (series on the same Liat® instrument)

148 G21124.1 (GE/mL 1.93E+07) = 18.6 [Ct ref. Cobas 6800: 25.2]

149 G21125.1 (GE/mL 2.76E+06) = 21.1 [Ct ref. Cobas 6800: 28.2]

150 G21126.1 (GE/mL 2.43E+05) = 24.5 [Ct ref. Cobas 6800: 32.0]

151 Ct-values of the dilutions

152 G21126-2 (1:10) = Ct 28.0

153 G21126-2 (1:100) = Ct 31.5

154 G21126-2 (1:1,000) Ct 35.5

155 G21126-2 (1:10,000) Ct 42 = negative

156 *Diagnostic performance*

157 Ct-values were converted into estimated virus concentrations per mL buffer using the  
158 standards listed above. Levels below  $10^6$  per mL buffer are considered as “weak positive”,  
159 between  $10^6$  and  $10^7$  are considered as “intermediate” and over  $10^7$  as high. Calculated virus  
160 concentrations below  $10^4$  are labelled as “borderline” (repeat measurement after 24-48h).

161 *Clinical endpoints*

162 Clinical endpoint are listed in table 3.

163 *Staff satisfaction questionnaire*

164 The questionnaire comprised of 11 questions and the opportunity of free text. The  
165 questionnaire is available in the supplement 2 (S2). N=37 members of staff, who were  
166 involved in the operation of the POC instrument participated. 89% of respondents  
167 performed more than 10 measurements with the Liat in and outside of the current study.  
168 73% performed more than 25 measurements and stated that they can integrate the POC  
169 testing very well into the treatment routine in the ED. More than 70% of respondents stated  
170 they were satisfied with the usability of the devices and 62% were satisfied with sample  
171 handling. In contrast 5% were unsatisfied with sample handling: holding the cartridges and

172 pipettes simultaneously as well as the need to pipette beside the patient were points of  
173 criticism.

174 In this current context 46% of the respondents were unsatisfied with hygienic conditions of  
175 sample processing. Main aspects for concerns were the location of the devices and the  
176 safety for employees and patients. 57% of respondents stated they were satisfied with  
177 display of results, 38% were undecided. Medical employees indicated that there should be  
178 greater ability to print the results directly at the POC instrument. Furthermore the results of  
179 POC testing had various effects. For one, they had an impact on interactions with the  
180 patients for 81% of the respondents, in addition, 86% of the respondents stated that the  
181 available results were valued by further departments/wards.

182

### 183 Discussion

184 The current study confirms(8, 9) the high accuracy of the Liat® SARS-CoV-2 POC PCR test and  
185 for the first time the feasibility of use in a large and busy ED with digital integration in the  
186 laboratory and hospital information systems (see figure 1).

#### 187 *POC test performance*

188 The use of POC systems are always intended to shorten the turn-around-time (TAT). As in  
189 other studies, this could be shown here. Nevertheless, more important than the pure TAT is  
190 (1) the “time to actionable result” time of the attending physicians and (2) whether any  
191 important clinical action follows a POC test result. In our study we could clearly show that a  
192 majority of SARS-CoV-2 POC test results was available before an urgent care process has  
193 been started. Nevertheless, although the pure testing time of the instrument is 20min, the  
194 median time from admission to result was 102min, reflecting that there has been a delay in



195 the implementation of the ED test strategy at the time of this study. As the test strategy is  
196 now standard in our institution and test capacities are sufficient, this time may be shorter in  
197 current routine care. The accuracy of the test results was 100%, although semi-  
198 quantification revealed some differences (see table 2). The sensitivity of the POC instrument  
199 seems to be comparable to the reference standard, which is an advantage compared to  
200 other POC PCR systems, where 1-2% false negatives are reported(7).

#### 201 *Digital integration*

202 Digital integration is a success factor under several aspects: (1) The digital order of the test  
203 including a standard label for the test tube ensures that the risk to mix up samples is  
204 minimized. (2) As the major incentive for the SARS-CoV-2 POC PCR is to speed up a complex  
205 pathway for emergency patients, it is mandatory that the test results are available for  
206 treating units including the operating theatre, intensive care and stroke units etc. In  
207 addition, tests need to be repeated and for this, it is most beneficial to have the results of  
208 the initial POC testing in the same system as the other laboratory test results. (3) The  
209 laboratory with experts for molecular test are automatically in the loop and contribute to  
210 quality management. Meanwhile we transfer also the cycle threshold values and a standard  
211 laboratory report is done on the basis of the POC test. (4) The POC PCR is a more expensive  
212 measure and reimbursement needs to be complete. Having all results in the central system  
213 ensures that no test is overseen. We believe that the complete digital integration should be  
214 the standard of POC in the ED in general and have established this way of collaboration with  
215 the central laboratory earlier for POC of Troponin T(10).

#### 216 *Staff satisfaction*

217 The use of high end POC devices in the ED requires trained staff, who are able to follow  
218 demanding test protocols as in this study due to hygiene rules as described in detail above  
219 (see also S1 for details). Thus, it is most important to assess the staff perspective on  
220 innovative POC test strategies. The staff was mostly satisfied with the technical aspects  
221 including sample handling and the ease of use of the instrument. A major concern,  
222 expressed by 46% of the participants were hygiene aspects of the test procedure. Although  
223 the test process follows strictly the regulations, many nurses feel uneasy with the step of  
224 pipetting a potential infectious sample although being sufficiently protected. We think that  
225 one solution of for this challenge could be the use of inactivating lysis buffer in the test  
226 tubes(11). Currently, only transport media and saline are approved for the use with the  
227 instrument.

228 Finally, the majority of participants valued that all admission processes and the interaction  
229 with patients and colleagues is supported by the POC PCR.

### 230 *Perspectives*

231 The following future developments are necessary for the continuation of molecular POC  
232 testing in the ED.

- 233 1. Use of tubes with inactivating lysis buffer, to make the test safer for the users.  
234 Alternatively, laboratory workbenches needs to be integrated in the ED, which may  
235 be suitable some but no everywhere.
- 236 2. Transfer of cycle threshold (Ct) values to the LIS. Meanwhile, the Ct values are used  
237 to estimate virus concentrations in the buffer of swabs on the basis of measurement  
238 of virus standards. On the peak of the SARS-CoV-2 waves with many positive samples,  
239 this has less importance than in lower incidence times, because now, frequently

240 weak positive signals occur and those patients must not be sent to a COVID-19 ward,  
241 where they are placed at risk for an infection, which they might not have at  
242 admission. This innovation has been actually released and is tested currently in our  
243 ED. Ct-values are automatically translated into a medical report of positive test  
244 results as being “to be controlled”, “weak positive” [ $< 10^6$  virus copies/mL buffer] or  
245 “strong positive” [ $> 10^7$  virus copies/mL buffer] or intermediate positive in between  
246 of the other two categories.

247 3. Future epidemiology of SARS-CoV-2 and other virus diseases will require a more  
248 differentiated test approach. Thus, in an actual very low incidence phase and no  
249 influenza at all, we would prefer to use a single SARS-CoV-2 test. In pediatrics the  
250 combination of SARS-CoV-2 and RSV would be interesting and at winter time the  
251 current triple test or even the addition of RSV would be beneficial. Finally, for future  
252 instrument development, a standardization of the PCR cycles with central laboratory  
253 instruments could help.

#### 254 Clinical significance

255 Our study show that a fully digital integrated POC PCR test strategy improves fast and safe  
256 emergency processes in urgent patients under pandemic conditions in the ED.

#### 257 Conclusions

258 The POC-PCR testing in the emergency department is feasible and shows a very high  
259 diagnostic performance. The digital process integration is key for a high clinical impact in  
260 patients with acute indication for inpatient treatment.

#### 261 Acknowledgement

262 We acknowledge Clinical Research Unit (CRU) by Berlin Institute of Health (BIH), 10178  
263 Berlin, Germany for providing support regarding the use of the data management software  
264 (RedCap). We thank Dr. Victor Corman, Institute for Virology, Charité – Universitätsmedizin  
265 Berlin, providing the standard virus samples.

#### 266 Conflicts of interest

267 The authors declare funding from Roche Molecular Systems for the submitted work.

#### 268 Funding

269 This study was supported by a research grant from Roche Molecular Systems.

#### 270 References

- 271 1. Möckel M, Bachmann U, Behringer W, Pfäfflin F, Stegemann MS. How emergency  
272 departments prepare for virus disease outbreaks like COVID-19. European journal of  
273 emergency medicine : official journal of the European Society for Emergency Medicine.  
274 2020;27(3):161-2.
- 275 2. Möckel M, Stegemann MS, Burst V, Kümpers P, Risse J, Koehler FC, et al. Which  
276 parameters support disposition decision in suspected COVID-19 cases in the emergency  
277 department (ED): a German clinical cohort study. BMJ open. 2021;11(3):e044853.
- 278 3. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy  
279 for Containment. New England Journal of Medicine. 2020;383(22):e120.
- 280 4. Möckel M, Corman VM, Stegemann MS, Hofmann J, Stein A, Jones TC, et al. SARS-  
281 CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department.  
282 Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.  
283 2021;26(3):213-20.
- 284 5. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the  
285 bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for  
286 COVID-19 detection. Rna. 2020;26(7):771-83.

- 287 6. Perlitz B, Slagman A, Hitzek J, Riedlinger D, Möckel M. Point-of-care testing for  
288 influenza in a university emergency department: A prospective study. *Influenza and other*  
289 *respiratory viruses*. 2021.
- 290 7. McDonald S, Courtney DM, Clark AE, Muthukumar A, Lee F, Balani J, et al. Diagnostic  
291 Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency  
292 Department Setting. *Acad Emerg Med*. 2020;27(8):764-6.
- 293 8. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, et al. Clinical  
294 Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a  
295 Multicenter Study. *Journal of clinical microbiology*. 2021;59(2).
- 296 9. Tsang HF, Leung WMS, Chan LWC, Cho WCS, Wong SCC. Performance comparison of  
297 the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in  
298 nasopharyngeal swab and posterior oropharyngeal saliva. *Expert review of molecular*  
299 *diagnostics*. 2021;21(5):515-8.
- 300 10. Slagman A, von Recum J, Möckel M, Holert F, Meyer Zum Büschenfelde D, Müller C,  
301 et al. Diagnostic performance of a high-sensitive troponin T assay and a troponin T point of  
302 care assay in the clinical routine of an Emergency Department: A clinical cohort study.  
303 *International journal of cardiology*. 2017;230:454-60.
- 304 11. Daum LT, Fischer GW. Rapid and Safe Detection of SARS-CoV-2 and Influenza Virus  
305 RNA using Onsite qPCR Diagnostic Testing from Clinical Specimens Collected in Molecular  
306 Transport Medium. *The journal of applied laboratory medicine*. 2021.

307 Contributorship Statement

308 All authors were involved in the conception and design of the study. MB, AFR and AS  
309 planned the acquisition of data. MB and AS conducted the statistical analysis. JH and AS set  
310 up the connection to the virology laboratory, performed and interpreted the confirmation  
311 tests and supervised the study from the laboratory side. FH set up the local process standard  
312 and supervised test activities. JHi was responsible for the questionnaire. MM, MB and AS  
313 drafted the manuscript and serve as guarantors for the manuscript. All authors were  
314 involved in the interpretation of data, critically revised the manuscript for important  
315 intellectual content, approved the final version to be published and agreed to be

316 accountable for all aspects of the work. The corresponding author attests that all listed  
317 authors meet authorship criteria and that no others meeting the criteria have been omitted.

### 318 Table legends

#### 319 Table 1

320 a. Demographic and clinical characteristics of all patients who were tested positive or  
321 negative for SARS-CoV-2 by POC-PCR; values are median (25%-75% percentiles); \*, in n=6  
322 patient an invalid result occurred on the POC instrument. BMI, body mass index; BP,  
323 systemic arterial blood pressure.  
324 b. Symptoms and risk factors of all participants and patients who were tested positive or  
325 negative for SARS-CoV-2 by POC-PCR; \*, in n=6 patient an invalid result occurred on the POC  
326 instrument.

327 Table 2. Diagnostic accuracy of POC-PCR as compared to CL-PCR (reference method) in  
328 patients in urgent need for treatment. The resulting diagnostic performance values are:  
329 sensitivity 100% (95%-CI: 79-100), specificity 100% (95%-CI: 97-100), PPV and NPV 100%.

330 Table 3. Clinical endpoints of all patients who were tested positive or negative for SARS-CoV-  
331 2 by POC-PCR; \*, in n=6 patient an invalid result occurred on the POC instrument.

### 332 Figure Legends

333 Figure 1. Process of the digitally integrated SARS-CoV-2 POC

334 Figure 2. Patient flow diagram. For this implementation and feasibility study, n=200 tests  
335 were available.

336

Table 1a	All patients* (n=160)	SARS-CoV-2	SARS-CoV-2 POC
		POC-PCR positive patients (n=16)	POC PCR negative patients (n=138)
<b>Women % (n)</b>	43.1 (69)	50.0 (8)	41.3 (57)
<b>Age [years]</b>	68 (51-78)	68 (57-78)	67 (51-78)
<b>BMI [kg/m<sup>2</sup>]</b>	25 (22-31)	30 (25-33)	24 (22-29)
<b>Vital signs</b>			
<b>BP systolic [mmHg]</b>	135 (115-155)	128 (108-150)	135 (116-155)
<b>BP diastolic [mmHg]</b>	81 (69-90)	75 (60-90)	82 (71-93)
<b>Heart rate [1/min]</b>	90 (77-106)	88 (71-106)	92 (79-107)
<b>Body temperature [°C]</b>	36.7 (36.1-37.4)	36.9 (36.2-38)	36.6 (36-37.3)
<b>Respiratory rate [1/min]</b>	17 (15-22)	23 (16-20)	17 (15-22)
<b>Oxygen saturation [%]</b>	98 (94-100)	94 (86-98)	98 (95-100)
<b>Laboratory values</b>			
<b>pH (nmiss=15)</b>	7.36 (7.33-7.41)	7.38 (7.31-7.44)	7.37 (7.33-7.40)
<b>Sodium [mmol/L] (nmiss=4)</b>	140 (136-142)	140 (137-142)	140 (136-142)
<b>Potassium [mmol/L] (nmiss=19)</b>	4.1 (3.8-4.5)	4.4 (3.9-4.9)	4.1 (3.7-4.5)
<b>Glucose [mg/dl] (nmiss=4)</b>	136 (113-173)	138 (116-238)	133 (111-168)
<b>Lactate [mg/dl] (nmiss=4)</b>	17 (13-29)	19 (12-34)	17 (14-29)

337

Table 1b	All patients* (n=160)	SARS-CoV-2	SARS-CoV-2
		POC-PCR positive patients (n=16)	POC PCR negative patients (n=138)
<b>Symptoms % (n)</b>			
<b>Fever</b>	17.5 (28)	25.0 (4)	17.4 (24)
<b>Cough</b>	10.6 (17)	25.0 (4)	8.7 (12)
<b>Haemoptysis</b>	1.9 (3)	6.3 (1)	1.4 (2)
<b>Sore throat</b>	0 (0)	0 (0)	0 (0)
<b>Rhinitis</b>	0.6 (1)	0 (0)	0.7 (1)
<b>Headache/muscle pain</b>	8.8 (14)	12.5 (2)	8 (11)
<b>Dyspnea</b>	17.5 (28)	37.5 (6)	15.2 (21)
<b>GI-Symptoms</b>	5.6 (9)	6.3 (1)	5.8 (8)

Diarrhea	4.4 (7)	12.5 (2)	3.6 (5)
Nausea/emesis	13.1 (21)	12.5 (2)	13.8 (19)
Loss of smell	0 (0)	0 (0)	0 (0)
Abdominal pain	10 (16)	6.3 (1)	10.1 (14)
Chest pain	10.6 (17)	6.3 (1)	10.9 (15)
<b>Severe COVID-19 risk factors % (n)</b>			
Transplantation	3.8 (6)	0 (0)	4.3 (6)
Tumor	16.9 (27)	12.5 (2)	16.7 (23)
Cardiovascular disease	66.9 (107)	75.0 (12)	65.2 (90)
Respiratory disease	18.1 (29)	31.3 (5)	16.7 (23)
Renal disease	23.8 (38)	25.0 (4)	23.2 (32)
Hepatic disease	6.9 (11)	0 (0)	8.0 (11)
Pregnancy	1.3 (2)	6.3 (1)	0.7 (1)
Immunsuppression	10.6 (17)	0 (0)	12.3 (17)
Diabetes mellitus	23.1 (37)	31.3 (5)	21.0 (29)

338

339


Table 2	SARS-CoV-2 CL positive	Border-line	Weak	Inter-mediate	High	SARS-CoV-2 CL negative	No material	Total
SARS-CoV-2 POC positive	16					0		16
Borderline		2	1	0	0			
Weak		0	4	1	1			
Intermediate		0	0	0	2			
High		0	0	0	5			
SARS-CoV-2 POC negative	0					137	1	138
Error						6		6
Total	16					143	1	160

340



Table 3	All patients	SARS-CoV-2 POC-	SARS-CoV-2 POC-PCR
	(n=160)	PCR positive patients (n=16)	negative patients (n=138)
<b>Inclusion criteria for inpatient treatment % (n)</b>			
Acute severe trauma	5.6 (9)	6.3 (1)	5.8 (8)
Stroke	18.1 (29)	12.5 (2)	18.1 (25)
Myocardial Infarction	8.8 (14)	0 (0)	10.1 (14)
Urgent operation	22.5 (36)	0 (0)	25.4 (35)
Intervention needs within 6 hours after presentation	6.9 (11)	0 (0)	8.0 (11)
ICU admission needed within 6 hours after presentation	25.0 (40)	62.5 (10)	20.3 (28)
Other reasons	13.1 (21)	18.8 (3)	12.3 (17)
<b>Clinical Course</b>			
Intensive Care Unit % (n)	48.8 (78)	50.0 (8)	46.4 (64)
Intubation % (n)	15.6 (25)	18.8 (3)	13.8 (19)
Death % (n)*	10 (16)	25 (4)	7.2 (10)


341



\*TT, testing time

342

343



344